TSVT — 2Seventy Bio Income Statement
0.000.00%
- $260.65m
- $85.89m
- $37.86m
- 34
- 23
- 50
- 28
Annual income statement for 2Seventy Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 248 | 54.5 | 91.5 | 100 | 37.9 |
Cost of Revenue | |||||
Gross Profit | 243 | 52 | 74.9 | 83.5 | 19.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 386 | 368 | 355 | 338 | 153 |
Operating Profit | -138 | -314 | -263 | -238 | -115 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -120 | -292 | -254 | -218 | -57.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -120 | -292 | -254 | -218 | -57.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -120 | -292 | -254 | -218 | -57.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -120 | -292 | -254 | -218 | -57.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.14 | -12 | -6.86 | -4 | -1.6 |
Dividends per Share |